Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.

Ruane P, Strasser SI, Gane EJ, Hyland RH, Shao J, Dvory-Sobol H, Tran T, Stamm LM, Brainard DM, Nyberg L, Shafran S.

J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13067. [Epub ahead of print]

PMID:
30663168
2.

Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).

Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F, Ramji A, Shafran SD, McPhee F, Yang R, Noviello S, Linaberry M; ALLY-3C study team.

Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print]

PMID:
30382942
3.

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.

Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, McHutchison JG, Mo H, Svarovskaia E, Shafran SD.

J Infect Dis. 2018 Oct 20;218(11):1722-1729. doi: 10.1093/infdis/jiy401.

PMID:
29982508
4.

Mycobacterium chimaera Infection After Aortic Valve Replacement Presenting With Aortic Dissection and Pseudoaneurysm.

O'Neil CR, Taylor G, Smith S, Joffe AM, Antonation K, Shafran S, Kunimoto D.

Open Forum Infect Dis. 2018 Jan 24;5(2):ofy018. doi: 10.1093/ofid/ofy018. eCollection 2018 Feb.

5.

Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.

Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S.

J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6.

PMID:
29221887
6.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis.

Tan DHS, Hull MW, Yoong D, Tremblay C, O'Byrne P, Thomas R, Kille J, Baril JG, Cox J, Giguere P, Harris M, Hughes C, MacPherson P, O'Donnell S, Reimer J, Singh A, Barrett L, Bogoch I, Jollimore J, Lambert G, Lebouche B, Metz G, Rogers T, Shafran S; Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.

CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494. No abstract available. Erratum in: CMAJ. 2018 Jun 25;190(25):E782.

7.

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E.

J Viral Hepat. 2018 Feb;25(2):118-125. doi: 10.1111/jvh.12782. Epub 2017 Sep 14.

PMID:
28833938
8.

Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.

Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H.

Antivir Ther. 2018;23(3):229-238. doi: 10.3851/IMP3181.

PMID:
28650844
9.

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG.

Clin Infect Dis. 2017 Jul 1;65(1):13-19. doi: 10.1093/cid/cix289.

PMID:
28535298
10.

The multi-faceted dynamics of HIV-1 transmission in Northern Alberta: A combined analysis of virus genetic and public health data.

Vrancken B, Adachi D, Benedet M, Singh A, Read R, Shafran S, Taylor GD, Simmonds K, Sikora C, Lemey P, Charlton CL, Tang JW.

Infect Genet Evol. 2017 Aug;52:100-105. doi: 10.1016/j.meegid.2017.04.005. Epub 2017 Apr 18.

PMID:
28427935
11.

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR.

Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.

PMID:
28390869
12.

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B.

Gastroenterology. 2017 Jan;152(1):164-175.e4. doi: 10.1053/j.gastro.2016.09.045. Epub 2016 Oct 5.

PMID:
27720838
13.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C.

Can J Infect Dis Med Microbiol. 2016;2016:4385643. doi: 10.1155/2016/4385643. Epub 2016 Jul 4.

14.

Response to: Comment on "Hepatitis C and the Sex Trade".

Shafran SD.

Can J Gastroenterol Hepatol. 2016;2016:5474217. doi: 10.1155/2016/5474217. Epub 2016 Jun 28. No abstract available.

15.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.

World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

16.

Reply to Menard et al.

Shafran SD.

Clin Infect Dis. 2016 Apr 1;62(7):949-50. doi: 10.1093/cid/civ1217. Epub 2016 Jan 5. No abstract available.

PMID:
26740516
17.

Hepatitis C and the sex trade.

Shafran SD.

Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):405-6. No abstract available.

18.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.

19.

Live attenuated herpes zoster vaccine for HIV-infected adults.

Shafran SD.

HIV Med. 2016 Apr;17(4):305-10. doi: 10.1111/hiv.12311. Epub 2015 Aug 27.

20.

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.

Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S.

Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24.

PMID:
26202757
21.

HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials.

Shafran SD.

Clin Infect Dis. 2015 Oct 1;61(7):1127-34. doi: 10.1093/cid/civ438. Epub 2015 Jun 9.

PMID:
26060286
22.
23.
24.

Telaprevir activity is unaffected by the Q80K polymorphism in hepatitis C virus genotype 1a.

Shafran S.

Can J Gastroenterol Hepatol. 2014 Oct;28(9):510. No abstract available.

25.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
26.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
27.

Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta.

Pittman C, Plitt S, Birse T, Doucette K, Romanowski B, Cooper R, Houston S, Shafran S, Singh AE.

Can J Infect Dis Med Microbiol. 2014 Spring;25(1):e8-e13.

28.
29.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):217-38. Erratum in: Can J Infect Dis Med Microbiol. 2014;24(1):63.

30.

Treating Clostridium difficile infection.

Shafran DM, Shafran SD.

CMAJ. 2014 Apr 15;186(7):531. doi: 10.1503/cmaj.131315. Epub 2013 Dec 16. Review. No abstract available.

31.

Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Cooper C, Shafran S, Greenbloom S, Enns R, Farley J, Hilzenrat N, Williams K, Elkashab M, Abadir N, Neuman M.

Can J Gastroenterol Hepatol. 2014 Jan;28(1):35-40. Epub 2013 Nov 8.

32.

Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.

Gorfinkel IS, Aoki F, McNeil S, Dionne M, Shafran SD, Zickler P, Halperin S, Langley J, Bellamy A, Schulte J, Heineman T, Belshe R.

Int J STD AIDS. 2013 May;24(5):345-9. doi: 10.1177/0956462412472822.

PMID:
23970700
33.

Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir.

Hall JJ, Hughes CA, Foisy MM, Houston S, Shafran S.

Int J STD AIDS. 2013 Sep;24(9):748-52. doi: 10.1177/0956462413480723. Epub 2013 Jul 8.

PMID:
23970582
34.

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO.

Hepatology. 2013 Jun;57(6):2155-63. doi: 10.1002/hep.26386.

PMID:
23504636
35.

Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.

Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, Walmsley S; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group.

PLoS One. 2011 Mar 25;6(3):e17758. doi: 10.1371/journal.pone.0017758.

36.

Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

Rachlis A, Angel JB, Harris M, Shafran SD, Therrien R, Tremblay C, Wainberg MA.

Can J Infect Dis Med Microbiol. 2009 Fall;20(3):e67-80.

37.

Challenges in initiating antiretroviral therapy in 2010.

Tremblay CL, Baril JG, Fletcher D, Kilby D, Macpherson P, Shafran SD, Tyndall MW.

Can J Infect Dis Med Microbiol. 2010 Aug;21 Suppl C:1C-15C.

38.

Canadian clinical practice guidelines for invasive candidiasis in adults.

Bow EJ, Evans G, Fuller J, Laverdière M, Rotstein C, Rennie R, Shafran SD, Sheppard D, Carle S, Phillips P, Vinh DC.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50.

39.

Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.

Rachlis A, Harris M, Lalonde R, Shafran SD, Tremblay C, Wainberg MA, Walmsley S.

Can J Infect Dis Med Microbiol. 2010 Winter;21(4):159-72.

40.

Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.

Hills-Nieminen C, Hughes CA, Houston S, Shafran SD.

Ann Pharmacother. 2009 Dec;43(12):2117-20. doi: 10.1345/aph.1M393. Epub 2009 Nov 24.

PMID:
19934385
41.

Improving access to care by allowing self-referral to a hepatitis C clinic.

Doucette KE, Robson V, Shafran S, Kunimoto D.

Can J Gastroenterol. 2009 Jun;23(6):421-4.

42.

Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS.

Lalonde RG, Boivin G, Deschênes J, Hodge WG, Hopkins JJ, Klein AH, Lindley JI, Phillips P, Shafran SD, Walmsley S.

Can J Infect Dis Med Microbiol. 2004 Nov;15(6):327-35.

43.

Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients.

Baril JG, Lefebvre EA, Lalonde RG, Shafran SD, Conway B.

Can J Infect Dis. 2003 Jul;14(4):201-5.

44.

Isolated native tricuspid valve endocarditis caused by viridans streptococcus.

Swiston J, Shafran SD, Kassam N.

Can J Infect Dis. 2001 Sep;12(5):305-7.

45.

Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS.

HIV Clin Trials. 2007 Sep-Oct;8(5):259-68.

PMID:
17956827
46.

Management of chronic hepatitis C: consensus guidelines.

Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M.

Can J Gastroenterol. 2007 Jun;21 Suppl C:25C-34C.

47.

Management of chronic hepatitis B: consensus guidelines.

Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, Yoshida E, Renner E, Wong P, Deschênes M.

Can J Gastroenterol. 2007 Jun;21 Suppl C:5C-24C.

48.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S; ACCELERATE Investigators.

N Engl J Med. 2007 Jul 12;357(2):124-34.

50.

Supplemental Content

Loading ...
Support Center